Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Utah Medical Products (UTMD) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to 26.61%.

  • Utah Medical Products' EBIT Margin fell 68000.0% to 26.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 30.78%, marking a year-over-year decrease of 23600.0%. This contributed to the annual value of 6.83% for FY2024, which is 21600.0% up from last year.
  • Latest data reveals that Utah Medical Products reported EBIT Margin of 26.61% as of Q3 2025, which was down 68000.0% from 32.11% recorded in Q2 2025.
  • In the past 5 years, Utah Medical Products' EBIT Margin ranged from a high of 40.55% in Q3 2021 and a low of 26.61% during Q3 2025
  • Its 5-year average for EBIT Margin is 34.86%, with a median of 34.39% in 2023.
  • Per our database at Business Quant, Utah Medical Products' EBIT Margin soared by 153100bps in 2021 and then crashed by -79400bps in 2023.
  • Utah Medical Products' EBIT Margin (Quarter) stood at 39.72% in 2021, then fell by -6bps to 37.35% in 2022, then fell by -14bps to 31.98% in 2023, then grew by 0bps to 32.0% in 2024, then dropped by -17bps to 26.61% in 2025.
  • Its EBIT Margin stands at 26.61% for Q3 2025, versus 32.11% for Q2 2025 and 32.47% for Q1 2025.